Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338

European Journal of Pharmacology

Volumn 497, Issue 2, 2004, Pages 223-231

  Furuta, Shigeru ^a   Kamada, Emiko ^a   Omata, Takeshi ^a   Sugimoto, Tohru ^a   Kawabata, Yoshihiro ^a   Yonezawa, Keiko ^b   Wu, Xiaochun Cheryl ^c   Kurimoto, Tadashi ^a  

^a ZERIA PHARMACEUTICAL CO LTD   (Japan)

^b Drug Safety Testing Center Co

^c Cerep Inc   (United States)

Author keywords

Cisapride; CYP inhibition; hERG; Terfenadine; Z 338

Indexed keywords

5 MEPHENYTOIN; ALPHA NAPHTHOFLAVONE; ANILINE; BENZYLOXYRESORUFIN; BUFURALOL; CHLORZOXAZONE; CISAPRIDE; COUMARIN; CYCLOSPORIN A; CYTOCHROME P450 3A4; CYTOCHROME P450 ISOENZYME; DIETHYLDITHIOCARBAMIC ACID; ETHOXYRESORUFIN; GLUCURONIDE; GLYCOPROTEIN P; KETOCONAZOLE; METHOXSALEN; N [2 (DIISOPROPYLAMINO)ETHYL] 2 (2 HYDROXY 4,5 DIMETHOXYBENZAMIDO) 4 THIAZOLECARBOXAMIDE; N [2 (DIISOPROPYLAMINO)ETHYL] 2 [(2 HYDROXY 4,5 DIMETHOXYBENZOYL)AMINO] 1,3 THIAZOLE 4 CARBOXAMIDE; OMEPRAZOLE; ORPHENADRINE; POTASSIUM CHANNEL HERG; PROKINETIC AGENT; QUINIDINE; SULFAPHENAZOLE; TERFENADINE; TOLBUTAMIDE; TRANYLCYPROMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; URIDINE DERIVATIVE; URIDINE DIPHOSPHATE GLUCORONOSYLTRANSFERASE 1 POLYPEPTIDE A8; URIDINE DIPHOSPHATE GLUCORONOSYLTRANSFERASE 1 POLYPEPTIDE A9;

ARTICLE; CELL LINE; CONCENTRATION (PARAMETERS); DRUG METABOLISM; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; LIVER MICROSOME; MALE; PATCH CLAMP; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL;

EID: 4143074861     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.06.040     Document Type: Article

References (38)

1. A. Anantharam, A. Lewis, G. Panaghie, E. Gordon, Z.A. McCrossan, D.J. Lerner, and G.W. Abbott RNA interference reveals that endogenous Xenopus MinK-related peptides govern mammalian K+ channel function in oocyte expression studies J. Biol. Chem. 4 2003 11739 11745
2. T.A. Bedford, and D.J. Rowbotham Cisapride. Drug interactions of clinical significance Drug Safety 15 1996 167 175
3. G. Brown Foresee the problem Hosp. Pharm. Pract. (Canada) 5 1997 9 10
4. M.D. Burke, S. Thompson, C.R. Elcombe, J. Halpert, T. Haaparanta, and R.T. Mayer Ethoxy-, pentoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced cytochromes P-450 Biochem. Pharmacol. 34 1985 3337 3345
5. M.D. Burke, S. Thompson, R.J. Weaver, C.R. Wolf, and R.T. Mayer Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver Biochem. Pharmacol. 48 1994 923 936
6. T.K.H. Chang, F.J. Gonzalez, and D.J. Waxman Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450 Arch. Biochem. Biophys. 311 1994 437 442
7. M. Dixon The determination of enzyme inhibitor constants Biochem. J. 55 1953 170 171
8. G.K. Dresser, J.D. Spence, and D.G. Bailey Pharmacokinetic†"pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition Clin. Pharmacokinet. 38 2000 41 57
9. S. Furuta, E. Kamada, T. Suzuki, T. Sugimoto, Y. Kawabata, Y. Shinozaki, and H. Sano Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole Xenobiotica 31 2001 1 10
10. S. Furuta, H. Miyahara, T. Sugimoto, and H. Sano LC determination of Z-338, novel gastroprokinetic agent in dog plasma by SCX solid phase extraction J. Pharm. Biomed. Anal. 25 2001 599 603
11. S. Furuta, N. Akagawa, E. Kamada, A. Hiyama, Y. Kawabata, N. Kowata, A. Inaba, A. Matthews, M. Hall, and T. Kurimoto Involvement of CYP2C9 and UGT2B7 in the metabolism of zaltoprofen, a nonsteroidal anti-inflammatory drug, and its lack of clinically significant CYP inhibition potential Br. J. Clin. Pharmacol. 54 2002 295 303
12. D.A. Garteiz, R.H. Hook, B.J. Walker, and R.A. Okerholm Pharmacokinetics and biotransformation studies of terfenadine in man Arzneim.-Forsch. 32 1982 1185 1190
13. J. Hunter, M.A. Jepson, T. Tsuruo, N.L. Simmons, and B.H. Hirst Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells J. Biol. Chem. 268 1993 14991 14997
14. S. Imaoka, Y. Terano, and Y. Funae Expression of four phenobarbital-inducible cytochrome P-450s in liver, kidney, and lung of rats J. Biochem. 105 1989 939 945
15. K. Ito, T. Iwatsubo, S. Kanamitsu, K. Ueda, H. Suzuki, and Y. Sugiyama Prediction of pharmacokinetic alterations caused by drugâ€"drug interactions: metabolic interaction in the liver Pharmacol. Rev. 50 1998 387 411
16. K. Ito, K. Chiba, M. Horikawa, M. Ishigami, N. Mizuno, J. Aoki, Y. Gotoh, T. Iwatsubo, S. Kanamitsu, M. Kato, I. Kawahara, K. Niinuma, A. Nishino, N. Sato, Y. Tsukamoto, K. Ueda, T. Itoh, and Y. Sugiyama Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data? AAPS Pharm. Sci. 4 2002 25
17. M. Jurima-Romet, K. Crawford, T. Cyr, and T. Inaba Terfenadine metabolism in human liver. In vitro inhibition by macrolide antibiotics and azole antifungals Drug Metab. Dispos. 22 1994 849 857
18. R.G. Knodell, S.D. Hall, G.R. Wilkinson, and F.P. Guengerich Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition J. Pharmacol. Exp. Ther. 241 1987 1112 1119
19. G.A. Leeson, K.Y. Chan, W.C. Knapp, S.A. Biedenbach, G.J. Wright, and R.A. Okerholm Metabolic disposition of terfenadine in laboratory animals Arzneim.-Forsch. 32 1982 1173 1178
20. D. McTavish, K.L. Goa, and M. Ferrill Terfenadine. An updated review of its pharmacological properties and therapeutic efficacy Drugs 39 1990 552 574
21. E.L. Michalets, and C.R. Williams Drug interactions with cisapride: clinical implications Clin. Pharmacokinet. 39 2000 49 75
22. M. Michiels, J. Monbaliu, R. Hendriks, R. Geerts, R. Woestenborghs, and J. Heykants Pharmacokinetics and tissue distribution of the new gastrokinetic agent cisapride in rat, rabbit and dog Arzneim.-Forsch. 37 1987 1159 1167
23. J.O. Miners, and D.J. Birkett Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9 Methods Enzymol. 272 1996 139 145
24. H. Miyake Drugs in Japan, Ethical drugs 25th ed. 2002 Japan Pharmaceutical Information Center Jiho, Tokyo, Japan
25. T. Nakajima, H. Nawata, and Y. Ito Z-338, a newly synthetized carboxyamide derivative, stimulates gastric motility through enhancing the excitatory neurotransmission J. Smooth Muscle Res. 36 2000 69 81
26. M. Ogishima, M. Kaibara, S. Ueki, T. Kurimoto, and K. Taniyama Z-338 facilitates acetylcholine release from enteric neurons due to blockade of muscarinic autoreceptors in guinea pig stomach J. Pharmacol. Exp. Ther. 294 2000 33 37
27. Oliver, S.D., Ward, C., Ward, J., Kato, H., Saito, Y., Furuta, S., 2000. Z-338: Phase I, single and multiple oral dose, safety, tolerability and pharmacokinetic studies in healthy male subjects. Br. J. Clin. Pharmacol. Abstract of the joint meeting of VII World Conference on Clinical Pharmacology and Therapeutics IUPHAR-Division of Clinical Pharmacology and 4th Congress of the European Association for Clinical Pharmacology and Therapeutics (EACPT) in Florence, 244.
28. I. Paakkari Cardiotoxicity of new antihistamines and cisapride Toxicol. Lett. 28 127 2002 279 284
29. R. Pelov, L. Tankova, and I. Krushkov The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe? Vutr. Boles. 31 1999 5 9
30. R. Peter, R. Böcker, P.H. Beaune, M. Iwasaki, F.P. Guengerich, and C.S. Yang Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1 Chem. Res. Toxicol. 3 1990 566 573
31. A. Radominska-Pandya, P.J. Czernik, J.M. Little, E. Battaglia, and P.I. Mackenzie Structural and functional studies of UDP-glucuronosyltransferases Drug Metab. Rev. 31 1999 817 899
32. D. Rampe, M.L. Roy, A. Dennis, and A.M. Brown A mechanism for the proarrhythmic effects of cisapride (propulsid): high affinity blockade of the human cardiac potassium channel HERG FEBS Lett. 3 1997 28 32
33. Y. Shiina, and T. Miwa Phase I study of cisapride: 1. Single oral dosing study J. Clin. Pharm. Ther. 16 1985 489 501 (Jan.)
34. C. Simard, G.E. O'Hara, J. Prévost, R. Guilbaud, R. Massé, and J. Turgeon Study of the drug-drug interaction between simvastatin and cisapride in man Eur. J. Clin. Pharmacol. 57 2001 229 234
35. S.A. Wrighton, J.C. Stevens, G.W. Becker, and M. VandenBranden Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation Arch. Biochem. Biophys. 306 1993 240 245
36. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno A pharmacokinetic analysis program (multi) for microcomputer J. Pharmacobio-Dyn. 4 1981 879 885
37. H. Yamazaki, Z. Guo, M. Persmark, M. Mimura, K. Inoue, F.P. Guengerich, and T. Shimada Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes Mol. Pharmacol. 46 1994 568 577
38. C.H. Yun, R.A. Okerholm, and F.P. Guengerich Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation Drug Metab. Dispos. 21 1993 403 409